EUVIMEDEUVIMED entdecken
Vergleichsstudie

Fentanyl dose-sparing in polyarthritic rats requires full agonism at 5-HT1A receptors: Comparison between NLX-112, (±)8-OH-DPAT, and buspirone

Ronan Depoortere, Laurent Bardin, Adrian Newman-Tancredi

Journal of Opioid Management · 2024

DOI: 10.5055/jom.0874 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Opioid Management, 2024. Verfasst von Ronan Depoortere und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neurolixis SAS, Castres, France. ORCID: https://orcid.org/0000-0003-0970-420X. Hauptthemen laut MEDLINE: Buspirone, Serotonin 5-HT1 Receptor Agonists, Receptor, Serotonin, 5-HT1A, 8-Hydroxy-2-(di-n-propylamino)tetralin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

NLX-112 (a.k.a. F13640, befiradol) is a highly selective and fully efficacious agonist at 5-hydroxytryptamine (5-HT1A) receptors. It has been shown to be robustly and potently active in nociceptive, neuropathic and traumatic pain models in rats and mice. In particular, NLX-112 decreases oral fentanyl self-administration (FSA) in polyarthritic rats, ie, it has opioid dose-sparing effects.

Objective

To examine if the dose-sparing effects of NLX-112 in polyarthritic rats are shared by other 5-HT1A ligands: the prototypical 5-HT1A receptor agonist 8-HYDROXY-2-(DI-n-PROPYLAMINO)TETRALIN ((±)8-OH-DPAT), and the 5-HT1A receptor partial agonist and weak dopamine D2 receptor blocker, buspirone.

Design

Polyarthritis was induced by inoculating rats with heat-killed Mycobacterium butyricum. They then had access to either a fentanyl (0.008 mg/mL) or a sweetened solution in their home cage. NLX-112, (±)8-OH-DPAT, or buspirone was administered via an osmotic minipump (5 μL/h) during a 2-week infusion period from day 14 to day 28 post-inoculation with Mycobacterium butyricum. Control infusions consisted of sterile 0.9 percent NaCl.

Results

NLX-112 (0.63 mg/day) significantly decreased FSA by 47 percent and increased total fluid consumption (TFC) by 7 percent (vehicle-loaded minipumps as controls). Both (±)8-OH-DPAT and buspirone (0.63 and 2.5 mg/day, respectively) failed to reduce FSA; (±)8-OH-DPAT did not modify TFC, while buspirone significantly decreased it by 17 percent.

Conclusions

These results suggest that oral FSA dose-sparing effect, in this rat polyarthritis pain model, requires high efficacy activation of 5-HT1A receptors, such as that afforded by NLX-112. By contrast, the agonist efficacy of (±)8-OH-DPAT and buspirone seems insufficient for FSA dose-sparing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuspironeSerotonin 5-HT1 Receptor AgonistsReceptor, Serotonin, 5-HT1A8-Hydroxy-2-(di-n-propylamino)tetralinFentanylAnimalsMaleRatsAnalgesics, OpioidRats, Sprague-DawleyDose-Response Relationship, DrugArthritis, ExperimentalArthritisPiperidinesPyridines

Substanzen

BuspironeSerotonin 5-HT1 Receptor AgonistsReceptor, Serotonin, 5-HT1A8-Hydroxy-2-(di-n-propylamino)tetralinFentanylbefiradolAnalgesics, OpioidPiperidinesPyridines

Autor:innen und Institutionen

  • Neurolixis SAS, Castres, France. ORCID: https://orcid.org/0000-0003-0970-420X.
  • Pierre Fabre Laboratories, Castres, France.
  • Neurolixis SAS, Castres, France.

Zitieren

APA

Depoortere, R., Bardin, L., & Newman-Tancredi, A. (2024). Fentanyl dose-sparing in polyarthritic rats requires full agonism at 5-HT1A receptors: Comparison between NLX-112, (±)8-OH-DPAT, and buspirone. Journal of Opioid Management. https://doi.org/10.5055/jom.0874

Vancouver

Depoortere R, Bardin L, Newman-Tancredi A. Fentanyl dose-sparing in polyarthritic rats requires full agonism at 5-HT1A receptors: Comparison between NLX-112, (±)8-OH-DPAT, and buspirone. Journal of Opioid Management. 2024. doi:10.5055/jom.0874

BibTeX
@article{Depoortere2024,
  author = {Depoortere, Ronan and Bardin, Laurent and Newman-Tancredi, Adrian},
  title = {Fentanyl dose-sparing in polyarthritic rats requires full agonism at 5-HT1A receptors: Comparison between NLX-112, (±)8-OH-DPAT, and buspirone},
  journal = {Journal of Opioid Management},
  year = {2024},
  doi = {10.5055/jom.0874}
}
Kostenlos starten →